CN1294922C - Medicine for treating osteoporosis and improving bone fracture healing - Google Patents
Medicine for treating osteoporosis and improving bone fracture healing Download PDFInfo
- Publication number
- CN1294922C CN1294922C CNB2005100183770A CN200510018377A CN1294922C CN 1294922 C CN1294922 C CN 1294922C CN B2005100183770 A CNB2005100183770 A CN B2005100183770A CN 200510018377 A CN200510018377 A CN 200510018377A CN 1294922 C CN1294922 C CN 1294922C
- Authority
- CN
- China
- Prior art keywords
- medicine
- osteoporosis
- radix
- radix angelicae
- fracture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating osteoporosis and promoting fracture union, which comprises the raw materials of (by weight share) 6 to 16 of drynaria, 6 to 12 of cyathula root, 4 to 1 0 of doubleteeth pubesscent angelica root, 8 to 16 pf himalayan teasel root, 3 to 9 of safflower, 3 to 6 of chuanxiong rhizome, 3 to 6 of angelica, 3 to 9 of eucommia bark and 3 to 9 of Chinese taxillus twig. The medicine is made by that according to the traditional Chinese medicine theory that the kidney governs the bones and engenders the marrow, the invigoration of the liver and kidney is predominant, and the treatment methods of spleen strengthening and stomach relaxation are also used and medicine is concentrated and prepared. Experimental researches from clinic and the inner aspect and the outer aspect of an animal body indicate that the medicine for treating the osteoporosis can adjust bone metabolism in essence so that the bone metabolism is converted to the direction of normanormality and balance.
Description
Technical field
The present invention relates to medicine, especially a kind of osteoporosis and medicine that promotes union of fracture for the treatment of.
Background technology
Bone is a kind of Biocomposite material, constitutes the support of bone by organic gel fibril network structure, and inorganic matter calcium, phosphorus are filled in wherein.Osteoporosis is to be reduced to principal character with general bone amount, osseous tissue microstructure degenerative change, and with sclerotin fragility increases, mechanical strength descends and risk of fractures raises an osteoid metabolic disease.Osteoporosis is divided two classes: a class mainly refers to the female patient in the menopause 15-20, and porous spot accounts for about 70% of this disease sum based on the spongy bone of spinal vertebral and extremities joint portion at this moment; Two classes mainly are meant the masculinity and femininity gerontal patient on 70 years old, and this moment, cortical bone also loosened, and sclerotin becomes fragile, attenuation, and the pulp cavity caliber increases, and accounts for 30% of sum.Women's postmenopausal osteoporosis patient, about about 6000-7500 ten thousand people of China, about whole world 2.2-2.5 hundred million people, still not having ideal medicine at present treats, main Therapeutic Method has: 1, controversies in hormone replacement in the elderly, need more than the life-time service 7-10, determined curative effect, but severe complications such as the carcinogenic rate of 5-10% and metrorrhagia are arranged; 2, the use of calcium preparation and fluoride preparation can improve the density of bone, but because of not improving the metabolism of bone, increase the fragility of bone on the contrary; 3, the use of phosphate preparation, it can suppress osteoclast activity, but can not promote skeletonization; 4, the use of XIANLING GUBAO, the Chinese medicine preparation of producing by Guizhou celestial miraculous cure industry company limited, state's internal therapy should the most representative Chinese patent medicine of disease at present, determined curative effect.
Summary of the invention
Treatment osteoporosis that purpose of the present invention just provides a kind of determined curative effect, has no side effect, pure Chinese herbal medicine is made and the medicine that promotes union of fracture.
Treatment osteoporosis of the present invention and the medicine that promotes union of fracture, its active component is made up of following components in part by weight: Rhizoma Drynariae 6-16, Radix Cyathulae 6-12, Radix Angelicae Pubescentis 4-10, Radix Dipsaci 8-16, Flos Carthami 3-9, Rhizoma Chuanxiong 3-6, Radix Angelicae Sinensis 3-6, Cortex Eucommiae 3-9, Herba Taxilli 3-9.
Treatment osteoporosis of the present invention can be prepared into the common drug dosage form by formulation method routinely with the medicine that promotes union of fracture.
Treatment osteoporosis of the present invention with the preparation method of the medicine that promotes union of fracture is: choose raw material by above-mentioned composition, through screening, clean, concoct, dry, pulverize, sieve, encapsulated.
The property of medicine of each component raw material in the medicine of treatment osteoporosis of the present invention and promotion union of fracture:
Rhizoma Drynariae: can control the lumbago due to renal deficiency flaccidity of the lower limbs, Hiccough and deaf, chronic diarrhea.Promoting blood circulation and hemostasis is continuous hinders: being applicable to that falling winks frustrates injury of tendon and muscle fracture.Radix Cyathulae: invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.Be used for soreness of waist and knee joint, muscles and bones is unable, amenorrhea abdominal mass, dizziness due to hyperactivity of liver-YANG.Radix Angelicae Pubescentis: expelling wind and removing dampness, numbness relieving and pain relieving; Be used for anemofrigid-damp arthralgia, lumbocrural pain, few cloudy volt wind headache.Radix Dipsaci: invigorating the liver and kidney, bone and muscle strengthening, continuous folding is hindered, and ends metrorrhagia; Be used for soreness of the waist and knees, rheumatic arthralgia, the metrorrhagia warp is many, vaginal bleeding during pregnancy hematochezia, injury from falling down.Flos Carthami: promoting blood circulation to restore menstrual flow, eliminating stasis to stop pain; Be used for amenorrhea, dysmenorrhea, lochia is not all right, note of the ancient Chinese abdominal mass mass in the abdomen, injury from falling down, skin infection swells and ache.Rhizoma Chuanxiong: blood-activating and qi-promoting, wind-expelling pain-stopping.Be used for menoxenia, amenorrhea dysmenorrhea, abdominal mass stomachache, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia.Radix Angelicae Sinensis: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.The Cortex Eucommiae: invigorating the liver and kidney, bone and muscle strengthening, antiabortive.Be used for lumbago due to renal deficiency, muscles and bones is unable, blood leaking in gestation, frequent fetal movement; Vascular hypertension.Herba Taxilli: invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive.Be used for that rheumatic arthralgia, soreness of the waist and knees, muscles and bones are unable, frequent fetal movement, early abortion, vascular hypertension.
The medicine of treatment osteoporosis of the present invention and promotion union of fracture is the theory according to the traditional Chinese medical science " the kidney generating marrow and dominating bone ", based on liver and kidney tonifying, takes into account method of treatment such as spleen invigorating peace stomach, blood circulation promoting and blood stasis dispelling, and selected medicine is formulated.It is monarch drug with the Rhizoma Drynariae, and the Cortex Eucommiae, Herba Taxilli, Radix Dipsaci are ministerial drug, and Rhizoma Chuanxiong, Radix Angelicae Sinensis, Flos Carthami are adjuvant drug, and Radix Angelicae Pubescentis, Radix Cyathulae are messenger drug, and compatibility is based on Chinese medicine " organic conception " and " treatment of disease must aim at its pathogenesis " two big rules.
Treatment osteoporosis of the present invention and the medicine that promotes union of fracture, through China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute's animal prerun, test method and result:
One, to the osteoporotic influence of castration mouse
1, method:
The female ICR mice that grows up is anaesthetized descending bilateral ovaries enucleation at pentobarbital sodium, postoperative intramuscular injection penicillin three days, and 10,000 units/only, two weeks of postoperative begin the administration of dividing into groups, and establish normal control group and sham operated rats with batch animal.Neuter is divided into castration moulding group, medicine of the present invention (LG) 16g/kg, 8g/kg, three dosage groups of 4g/kg (calculating) by the per kilogram of body weight crude drug, XIANLING GUBAO 800mg/kg group, more than respectively organize every day gastric infusion once, volume is 0.2ml/10g, 7 weeks of successive administration, estrogen group 2mg/kg weekly intramuscular injection once, continuous 7 weeks.24h after the last administration (fasting 16h) animal causes death from the eye socket blood-letting, gets femur and measures length, transverse diameter, dry weight, grey heavy.Blood sample is surveyed serum alkaline phosphatase (ALP), acid phosphatase (ACP), Ca, P behind the centrifugal 15min of 3000rpm.Each is organized data and organizes a statistical with t check between group.
2, result:
The influence to the castration mouse blood parameters in 48 days of medicine of the present invention (LG) successive administration sees the following form:
| Group | Dosage g/ | Animal | Ca(mmol/L) | P(mmol/L) | ALP(U/L) | ACP(u/l) |
| Normal control Sham-operated control group castration model group LG LG LG Xianlinggubao oestradiol benzoate | - - - 4 8 16 0.8 0.002 | 14 17 11 12 11 9 11 11 | 2.58±0.18 2.55±0.66 2.67±0.09 2.71±0.14 2.63±0.15 2.59±0.08 0.31±0.99* 2.17±0.94 | 2.10±0.34 2.39±0.61 2.13±0.28 2.42±0.23 2.81±0.58* 2.34±0.38 2.48±0.32** 2.42±0.13** | 22.75±6.36 20.45±4.05 26.19±9.30 23.30±5.26 24.33±6.03 21.88±13.23 23.81±4.84 27.81±7.84 | 36.71±8.07 30.94±5.53 31.16±7.17 27.84±5.04 24.85±3.78* 21.34±6.37 20.5±7.31* 21.62±5.09* |
LG reduces activity of acid phosphatase in the serum in dosage dependence mode as seen from Table 1, little, middle dosage rising serum inorganic phosphorus content (with the castration matched group than P＜0.01).LG is similar to the effect of positive control drug XIANLING GUBAO to the effect trend of serum ACP and P, and estrogen has highly significant rising (P＜0.01) phosphatase acid serum activity to have highly significant to reduce (P＜0.001) than the castration model group to serum inorganic phosphorus content, alkaline phosphatase activities than the castration model group.
3, the influence of bone length, transverse diameter, dry weight, ash:
The influence to castration mouse femur length, transverse diameter, dry weight, ash in 48 days of LG successive administration, the result is as follows:
| Group | Dosage g/l | Animal | Length m m | Transverse diameter mm | Dry weight mg | Ash mg |
| Normal control sham-operation group castration model group LG Xianlinggubao estradiol | 4 8 16 0.8 0.0 02 | 14 14 17 12 11 9 11 12 | 15.46±0.47 15.62±0.62 15.92±0.35** 15.42±0.50** 15.71±0.72 15.31±0.46** 15.90±0.51 15.67±0.53 | 1.69±0.11 1.73±0.11 1.76±0.13 1.85±0.13 1.80±0.10 1.90±0.07** 1.90±0.11** 1.92±0.12** | 39.49±3.54 37.01±3.76 37.87±2.50 36.54±3.42 37.74±4.33 36.87±2.26 36.16±2.32 49.26±4.79** | 25.29±2.44 23.23±2.30 23.99±1.79 23.52±2.34 24.12±2.75 23.66±1.74 24.4±1.51 33.51±4.29 |
From 48 days 16g/kg of the visible LG administration of last table group significantly add castration mouse femur transverse diameter, reduce femur length (with model group than P＜0.01); Positive control drug estradiol, XIANLING GUBAO significantly increase the femur transverse diameter (with model group than P＜0.01); Estradiol also significantly increase femur dry weight, ash (with model group than P＜0.001).
Two, to the influence of rat osteoblast propagation and alkaline phosphatase activities
1, method
(1) pastille serum preparation: three new zealand rabbits are irritated stomach LG16.8g/kg dosage, and successive administration is three times in the 24h, and the 1h heart puncturing extracting blood prepares pastille serum after the last administration.Three new zealand rabbits irritate that the serum of cardiac puncture preparation is blank serum behind the ordinary water.Serum is through 56 ℃ of deactivation 30min, and is standby after the aseptic filtration.
(2) rat osteoblast is cultivated and the cell proliferation detection
Get the Wistar rat skull of new birth under the aseptic condition, isolate parietal bone and frontal bone, in D-HankS liquid, peel off the chopping of fibroid periosteum, through 0.25% trypsinization 15min, vibration in per 3 minutes once discards Digestive system, digests 2 times at 37 ℃ with 0.1% Collagen Type VI enzyme 10ml, each 60min, collect Digestive system, the centrifugal 5min of 1000rpm removes supernatant, with cell inoculation in the culture bottle that contains 20% calf serum F12 culture fluid, 37 ℃ of 5%CO
2Cultivate in the incubator, 24H changes liquid, cultivated when treating cell confluent cultures bottle in 2-3 days, the cultivation of going down to posterity, used experimental cell be the 3rd generation cell, be inoculated in every hole 0.2ml in 96 orifice plates by 30,000 cells/ML.Add variable concentrations and contain and be subjected to reagent liquid training base or pastille serum, establish blank serum contrast simultaneously, contrast of pastille training base and positive drug contrast, the multiple hole of each concentration 3-4.Cultivate 72h, change serum-free F
12The every hole 0.1ml of culture fluid adds 10ul 5mg/mlMTT solution, continues to cultivate 4h, and sucking-off 110ul culture fluid adds dimethyl sulfoxide 100ul, shakes evenly, and 570nm measures the absorbance in each hole on microplate reader.
(3) cell determination of alkaline phosphatase activity
Osteoblast grouping, dosing, cultivation are with two, 2.Get supernatant 100ul in cultivating 72, be used for determination of alkaline phosphatase activity, assay method is a King's method, and by specification carries out.
2, result
(1) LG pastille serum of the present invention the results are shown in following table to the influence of osteoblastic proliferation and alkaline phosphatase activities:
| Pastille serum | Dosage ul/ml | Osteoblastic proliferation rate % | Alkali phosphatase rate of rise % |
| LG pastille serum | 100 80 65 50 40 | 0.16 5.84 33.70 11.82 9.44 | 30.18 13.96 20.70 26.16 10.56 |
(2) LG medicine of the present invention directly adds the influence following table of external osteoblast culture systems to osteoblastic proliferation and alkaline phosphatase activities:
| Medicine name | Dosage ul/ml | Osteoblastic proliferation rate % | Alkali phosphatase rate of rise % |
| The LG medicine | 250 125 62.5 31.5 15.7 | -13.17 4.10 -12.43 -5.81 -31.91 | 35.12 18.73 18.43 17.16 13.99 |
Conclusion:
Medicine of the present invention (LG) 4g crude drug/kg-16g crude drug/7 weeks of kg successive administration reduces castration mouse phosphatase acid serum activity, rising serum inorganic phosphorus content; Increase the femur transverse diameter, suppress femur length and increase.The function of resisting osteoporosis of LG is similar to the XIANLING GUBAO effect.LG pastille serum demonstrates obvious facilitation to osteoblastic proliferation and alkaline phosphatase activities in the rat osteoblast vitro culture system.LG directly acts on rat osteoblast and promotes Alkaline Phosphatase, and the amount of having one effect relationship.In body, external two aspect researchs show that tentatively LG of the present invention has to a certain degree function of resisting osteoporosis to the examination animal model.
Show that from experimentatioies clinical and inside and outside two aspects of animal body treatment osteoporosis of the present invention can fundamentally be adjusted bone metabolism with the medicine that promotes union of fracture, makes it to transform to normal state balance direction.
The specific embodiment
Embodiment 1:
A kind of osteoporosis and medicine that promotes union of fracture for the treatment of, its active component is made up of following components in part by weight:
Rhizoma Drynariae 16, Radix Cyathulae 8, Radix Angelicae Pubescentis 6, Radix Dipsaci 15, Flos Carthami 4, Rhizoma Chuanxiong 5, Radix Angelicae Sinensis 6, the Cortex Eucommiae 4, Herba Taxilli 8.
Its preparation method is: choose raw material by above-mentioned composition, through screening, clean, concoct, dry, pulverize, sieve, encapsulated.
Embodiment 2:
A kind of osteoporosis and medicine that promotes union of fracture for the treatment of, its active component is made up of following components in part by weight:
Rhizoma Drynariae 8, Radix Cyathulae 10, Radix Angelicae Pubescentis 8, Radix Dipsaci 10, Flos Carthami 7, Rhizoma Chuanxiong 6, Radix Angelicae Sinensis 4, the Cortex Eucommiae 8, Herba Taxilli 6.
Its preparation method is identical with embodiment 1.
Embodiment 3:
A kind of osteoporosis and medicine that promotes union of fracture for the treatment of, its active component is made up of following components in part by weight:
Rhizoma Drynariae 10, Radix Cyathulae 6, Radix Angelicae Pubescentis 5, Radix Dipsaci 8, Flos Carthami 8, Rhizoma Chuanxiong 5, Radix Angelicae Sinensis 5, the Cortex Eucommiae 6, Herba Taxilli 3.
Its preparation method is identical with embodiment 1.
Claims (3)
1, a kind of osteoporosis and medicine that promotes union of fracture for the treatment of, it is characterized in that: its active component is made up of following components in part by weight: Rhizoma Drynariae 6-16, Radix Cyathulae 6-12, Radix Angelicae Pubescentis 4-10, Radix Dipsaci 8-16, Flos Carthami 3-9, Rhizoma Chuanxiong 3-6, Radix Angelicae Sinensis 3-6, Cortex Eucommiae 3-9, Herba Taxilli 3-9.
2, treatment osteoporosis according to claim 1 and the medicine that promotes union of fracture, it is characterized in that: its active component is made up of following components in part by weight: Rhizoma Drynariae 8, Radix Cyathulae 10, Radix Angelicae Pubescentis 8, Radix Dipsaci 10, Flos Carthami 7, Rhizoma Chuanxiong 6, Radix Angelicae Sinensis 4, the Cortex Eucommiae 8, Herba Taxilli 6.
3, treatment osteoporosis according to claim 1 and the medicine that promotes union of fracture, it is characterized in that: its active component is made up of following components in part by weight: Rhizoma Drynariae 10, Radix Cyathulae 6, Radix Angelicae Pubescentis 5, Radix Dipsaci 8, Flos Carthami 8, Rhizoma Chuanxiong 5, Radix Angelicae Sinensis 5, the Cortex Eucommiae 6, Herba Taxilli 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100183770A CN1294922C (en) | 2005-03-11 | 2005-03-11 | Medicine for treating osteoporosis and improving bone fracture healing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100183770A CN1294922C (en) | 2005-03-11 | 2005-03-11 | Medicine for treating osteoporosis and improving bone fracture healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682860A CN1682860A (en) | 2005-10-19 |
| CN1294922C true CN1294922C (en) | 2007-01-17 |
Family
ID=35262479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100183770A Expired - Fee Related CN1294922C (en) | 2005-03-11 | 2005-03-11 | Medicine for treating osteoporosis and improving bone fracture healing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1294922C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708266B (en) * | 2009-12-14 | 2011-04-27 | 耿爱芝 | Oral herbal decoction for treating osteoporosis |
| CN103142715B (en) * | 2013-03-13 | 2014-06-25 | 于复新 | Traditional Chinese medicine preparation for treating lumbar intervertebral disc herniation |
| CN103919908B (en) * | 2014-04-16 | 2016-03-02 | 泰山医学院 | Medicine of a kind of prevention and therapy disuse osteoporosis and preparation method thereof |
| CN104758503B (en) * | 2015-03-13 | 2019-02-01 | 广东药科大学 | It is a kind of promote union composition and its decocting liquid preparation method |
| CN106692834A (en) * | 2015-11-14 | 2017-05-24 | 张立 | Medicinal liquor for treating kidney deficiency type osteoporosis |
| CN108295166A (en) * | 2018-05-08 | 2018-07-20 | 葛新军 | A kind of paste formulation and preparation method and application of using medicine for external application that fracture |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150910A (en) * | 1996-04-18 | 1997-06-04 | 花茂时 | Osteophytosis pill and its compounding method |
| CN1400007A (en) * | 2002-06-10 | 2003-03-05 | 郭好建 | Oral Chinese medicine for curing osteoarthropathy |
-
2005
- 2005-03-11 CN CNB2005100183770A patent/CN1294922C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150910A (en) * | 1996-04-18 | 1997-06-04 | 花茂时 | Osteophytosis pill and its compounding method |
| CN1400007A (en) * | 2002-06-10 | 2003-03-05 | 郭好建 | Oral Chinese medicine for curing osteoarthropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682860A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1294922C (en) | Medicine for treating osteoporosis and improving bone fracture healing | |
| Sun et al. | Total flavonoids of rhizoma drynariae ameliorates bone formation and mineralization in BMP-Smad signaling pathway induced large tibial defect rats | |
| CN114042146B (en) | Bovine bone peptide composition and application thereof in preparation of medicines for regulating intestinal flora and preventing and treating osteoporosis | |
| CN109700947B (en) | Traditional Chinese medicine for treating steroid-induced femoral head necrosis and application thereof | |
| CN1927256A (en) | Upper, middle and lower part soup, and method for making same | |
| CN1323677C (en) | Medicine for osteoporosis | |
| CN1207022C (en) | Medicinal composition for promoting bone-fracture healing and bone-joint injure repairing | |
| CN101485774A (en) | Oral liquid for treating osteoporosis | |
| CN1781510A (en) | Use of sea-buckthorn fruit oil and/or fruit slag oil in preparing medicine for treating osteoporosis | |
| US11975052B2 (en) | Compound composition for improving bone health and preparation and application thereof | |
| CN100363021C (en) | Use of cajan seed and its extract in preparing medicine for treating osteal arthritis | |
| CN101302242B (en) | Novel use of ecdysterone | |
| CN1116070C (en) | Medical wine for treating rheumatism, fracture and injury and preparing process thereof | |
| CN114558088B (en) | Mongolian medicine compound for treating primary osteoporosis and application thereof | |
| CN100509023C (en) | Nutrient for cell growth, preparation method, and application of finished product thereof | |
| CN1208071C (en) | Bone setting pills for promoting fracture healing and its prepn process | |
| CN1211099C (en) | Zhenggutongbi pill for curing bone disunion, aseptic bone necrosis and chronic osteomyelitis and its preparing method | |
| CN102552386B (en) | Anti-osteoporosis Chinese medicinal preparation and preparation method thereof | |
| CN1241600C (en) | Chinese medicine for treating osteological diseases and its prepn process | |
| CN102028837B (en) | Method for preparing bone-treatment capsule | |
| CN1298381C (en) | Conception promoting pill | |
| CN1498629A (en) | Chinese traditional medicine for treating osteoporosis and its prepn. method | |
| CN1293891C (en) | Oteoporosis treating medicinal capsule and its preparation method | |
| CN113499388A (en) | Composition for treating osteoporosis and preparation method thereof | |
| CN1241604C (en) | Cervical vertebra disease capsule and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070117 Termination date: 20160311 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |